Hematologic Oncology | Specialty

Acalabrutinib Shows Noninferior PFS, Less Atrial Fibrillation Versus Ibrutinib in High-Risk CLL

January 26th 2021

January 26, 2021 - Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia.

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

January 26th 2021

Go-To Treatment Regimens in Mantle Cell Lymphoma

January 26th 2021

Rapid Readouts: Phase 2 JULIET Trial

January 26th 2021

Acalabrutinib Approved in Japan for Relapsed/Refractory CLL

January 25th 2021

January 25, 2021 - The Japanese Ministry of Health, Labour and Welfare approved the BTK inhibitor acalabrutinib for use in adult patients with relapsed/refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

January 25th 2021

MRD Monitoring in FLT3 ITD AML

January 25th 2021

Assessing MRD Status in AML

January 25th 2021

Management of Ocular Events From DREAMM-2 Regimen

January 25th 2021

Oncology Community Mourns Joseph V. Simone, MD

January 23rd 2021

Joseph V. Simone, MD, a pioneering clinical investigator and institutional leader in pediatric oncology who was recognized with a 2017 Giants of Cancer Care® award, died January 21 at the age of 85.

Determining How to Incorporate MRD Into Care Decisions for Myeloma

January 22nd 2021

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

Axicabtagene Ciloleucel Approved in Japan for Relapsed/Refractory LBCL

January 22nd 2021

January 22, 2021 — The Japan Ministry of Health, Labour and Welfare has approved the CAR T-cell therapy axicabtagene ciloleucel for use in the treatment of adult patients with certain relapsed/refractory large B-cell lymphomas.

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

January 22nd 2021

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

January 22nd 2021

ASH 2020 Updates in CLL

January 22nd 2021

Forecasting Future Advances Across Oncology

January 21st 2021

Expert discuss their expectations for research and drug development in oncology in the new year.

Parsaclisib Yields Encouraging Clinical Activity in Marginal Zone Lymphoma

January 21st 2021

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

January 21st 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

Adult Nonmalignant Hematology Is an Endangered Field That Merits Protection

January 21st 2021

The scope of adult nonmalignant hematology can be broad and includes thrombotic and hemorrhagic disorders, transfusion medicine, hemoglobin disorders including sickle cell disease and thalassemia, anemia, thrombocytopenia, leukocytosis, leukopenia, and disorders of iron metabolism.

PANORAMA 3 Study Resets Expectations for Panobinostat in Multiple Myeloma

January 21st 2021

Andrew Spencer, MD, MBBS, FRACP, FRCPA discusses the significance of the PANORAMA 3 study in multiple myeloma.